Woodline Partners LP - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Woodline Partners LP ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q2 2024$10,965,069
-41.3%
266,790
-33.3%
0.10%
-39.0%
Q1 2024$18,681,790
-2.4%
400,1240.0%0.17%
-17.3%
Q4 2023$19,133,930
+161.2%
400,124
+94.7%
0.21%
+141.9%
Q3 2023$7,325,469
-32.9%
205,483
-13.1%
0.09%
-33.3%
Q2 2023$10,912,697236,5640.13%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2023
NameSharesValueWeighting ↓
First Light Asset Management, LLC 217,459$24,760,0001.64%
Motley Fool Asset Management LLC 152,326$17,344,0001.25%
Rock Springs Capital Management LP 450,000$51,237,0001.12%
AtonRa Partners 21,017$2,393,0001.07%
SECTORAL ASSET MANAGEMENT INC 112,200$12,775,0000.97%
EMERALD ADVISERS, LLC 228,368$26,002,0000.94%
EMERALD MUTUAL FUND ADVISERS TRUST 239,023$27,215,0000.90%
FEDERATED HERMES, INC. 3,912,408$445,467,0000.86%
HealthCor Management, L.P. 207,610$23,638,0000.84%
Atika Capital Management LLC 66,000$7,515,0000.65%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders